2023
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Karasaki T, Moore D, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir M, Watkins T, Grigoriadis K, Huebner A, Hill M, Frankell A, Abbosh C, Puttick C, Zhai H, Gimeno-Valiente F, Saghafinia S, Kanu N, Dietzen M, Pich O, Lim E, Martínez-Ruiz C, Black J, Biswas D, Campbell B, Lee C, Colliver E, Enfield K, Hessey S, Hiley C, Zaccaria S, Litchfield K, Birkbak N, Cadieux E, Demeulemeester J, Van Loo P, Adusumilli P, Tan K, Cheema W, Sanchez-Vega F, Jones D, Rekhtman N, Travis W, Hackshaw A, Marafioti T, Salgado R, Le Quesne J, Nicholson A, McGranahan N, Swanton C, Jamal-Hanjani M. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine 2023, 29: 833-845. PMID: 37045996, PMCID: PMC7614478, DOI: 10.1038/s41591-023-02230-w.Peer-Reviewed Original ResearchConceptsPrimary tumor regionLung adenocarcinomaPresence of micropapillary patternLoss of chromosome 3pSolid pattern tumorsHigh-grade patternsClonal evolution analysisSomatic copy number alterationsTumor regionLoss of heterozygosityWhole-exome sequencing dataCopy number alterationsAdenocarcinoma morphologyIntrathoracic recurrenceLepidic tumorsRNA sequencing dataMicropapillary patternRelapse riskGene alterationsMetastatic samplesHistological spectrumMicropapillary tumorsChromosome 3pHigh-gradeHistopathological analysis
2022
Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study
Hiley C, Litchfield K, Pich O, Moore D, Naceur-Lombardelli C, Veeriah S, Bakir M, Summan S, Grigoriadis K, Ruiz C, Puttick C, Enfield K, Ward S, Frankell A, Biswas D, Rosenthal R, Birkbak N, Jamal-Hanjani M, McGranahan N, Swanton C, Consortium T. Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study. Cancer Research 2022, 82: 645-645. DOI: 10.1158/1538-7445.am2022-645.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor mutational burdenIntra-tumor heterogeneityIntratumoral heterogeneityCancer Cohort StudyImmunotherapy biomarkersTumor regionAmerican Association for Cancer Research annual meetingsPredictors of response to immunotherapyCohort studyPrediction of immunotherapy responseTumor purityNeo-adjuvant settingResponse to immunotherapyFirst-line therapyImpact of intratumoral heterogeneityCell lung cancerMisclassification of patientsWhole-exome sequencingHeterogeneity of expressionMetastatic settingPDL1 immunohistochemistryPrimary tumorImmunotherapy responseMutational burden